22nd Century Group Inc. is a US-based biotechnology firm that develops genetically engineered low-nicotine tobacco products aimed at reducing the health risks of traditional tobacco use. Founded in 1986 and currently led by CEO Michael Victus, the company capitalizes on its proprietary genetic technologies to secure licensing deals and strategic industry collaborations. With a market capitalization around $200 million and modest annual revenues, it has carved out a specialized niche in the tobacco and emerging cannabis sectors. The firm is actively expanding its product pipeline and pursuing regulatory and market opportunities to drive future growth.